In July 2009, the CCRD received a five-year renewal of $11.2 million in total funding to continue the development of the cancer research effort at Rhode Island Hospital. The Center for Cancer Research Development will continue to move forward with its mission to create, interpret and apply new knowledge based on original, collaborative, multidisciplinary laboratory studies to uncover the cellular and molecular pathways leading to gastrointestinal cancer arising in the liver, intestine, pancreas and colon. The acquisition of such knowledge will be facilitated by creating an environment that fosters career development of promising investigators and provides state-of-the-art technologies required for cutting-edge research. Basic knowledge gained will be used to design and implement novel diagnostic and treatment protocols benefiting patients in the Comprehensive Cancer Center and the community at large.
The mission of COBRE Center for Cancer Research Development at Rhode Island Hospital is to create, interpret and apply new knowledge based on original, collaborative, multidisciplinary laboratory studies of the cellular and molecular pathways leading to carcinoma. Such knowledge will be generated in an environment that fosters career development of promising junior investigators and employs cutting-edge methodology and applications to further our understanding of the cancer process. Basic knowledge gained will be used to design and implement novel diagnostic and treatment protocols to benefit the hospital's patients and the community at large.
The COBRE Center provides junior investigators access to the wisdom and experience of senior faculty mentors as well as cutting-edge technologies in biomedical research that were previously unavailable in Rhode Island. The mentoring relationship helps investigators hone their research and investigative skills so that they will ultimately be able to support their research through their own grant awards.
CCRD activities including grant writing workshops, symposia, seminars and biannual advisory committee meetings will be managed and directed by the COBRE CCRD's administrative core. The proteomics core will continue to provide the latest technologies and methodologies for analyzing changes in the protein expression profiles that occur when normal cells become cancerous. The goal is to find new markers for early detection and diagnosis. The molecular pathology core will continue to build a tissue bank of valuable human and animal tissues and will offer upgraded services for laser capture microdissection, microtissue array preparation, and QPCR. Proteomics and molecular pathology core directors will also collaborate in the development of new applications for a recently acquired imaging mass spectrometer, applications that we expect to provide new strategies for biomarker discovery and new diagnostic tools for the clinician.
This website was made possible by NIH Grant Number RR-P20 RR17695 from the Institutional Development Award (IDeA) Program of the National Center for Research Resources/Center of Biological Research Excellence (COBRE).
One Hoppin Street • Providence, RI 02903Phone: 401-444-2871 • email: ESmith6@lifespan.org